Please login to the form below

Not currently logged in
Email:
Password:

Lilly forms hypoglycaemia drug pact

Eli Lilly has acquired worldwide commercialisation rights to a developmental hypoglycaemia therapy from Marcadia Biotech

Eli Lilly has acquired worldwide commercialisation rights to a glucagon analogue under development for severe hypoglycaemia in people with diabetes from Marcadia Biotech. Marcadia is an Indiana-based company founded five years ago to focus on developing drugs for diabetes and obesity using proprietary peptide chemistry.

The companies hope that the hypoglycaemia therapy, which is currently in preclinical development, will provide an alternative to currently marketed glucagon products, which need to be refrigerated and also must be reconstituted from a powder before they can be injected. Lilly and Marcadia aim to develop this new product as a premixed solution in a convenient single-use auto-injection "pen" device that can be stored at room temperature.

The agreement between the two companies covers the glucagon analogue MAR531 and also a stable of related back-up compounds. The deal calls for Marcadia to continue to oversee development of the product through US approval, but gives Lilly responsibility for regulatory approval in countries outside the US and for commercialisation worldwide.

MAR531 and the related compounds were discovered through Marcadia's sponsored research agreement with Indiana University, Bloomington. Financial terms of the deal with Lilly were not disclosed.

Lilly is already a leader in the diabetes space, with a portfolio that includes the type II diabetes drug Byetta (exenatide).

29th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics